Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913878 | 1.00 | HDAC8 (0.64) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| SCHEMBL28891745 | 0.81 | HDAC8 (0.66) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| SCHEMBL3825273 | 0.81 | HDAC8 (0.66) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| SCHEMBL15854253 | 0.81 | SMN1; SMN2 (0.52) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| SCHEMBL11480056 | 0.80 | HDAC8 (0.73) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL17219413 | 0.79 | SMN1; SMN2 (0.51) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| SCHEMBL30071536 | 0.79 | HDAC8 (0.68) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| SCHEMBL5433891 | 0.79 | HDAC8 (0.68) | HDAC8HDAC6HPGDALDH1A1RAB9A | |
| SCHEMBL15695524 | 0.79 | HPGD (0.48) | HPGDALDH1A1RAB9ASMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL17219417 | 0.79 | SMN1; SMN2 (0.51) | HDAC8HDAC6HPGDALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2509596-B1 | GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | disclosed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-20180071285-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-03-15 | — | — | US | disclosed |
| US-20170196908-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY | 2017-07-13 | — | — | US | disclosed |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-12-04 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | HDAC8 381/4885HDAC6 66/4885HPGD 372/4885 |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | HDAC8 1811/4885HDAC6 1435/4885HPGD 483/4885 |
| US-20180071285-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | HDAC8 1811/4885HDAC6 1435/4885HPGD 483/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | HDAC8 2177/4885HDAC6 1424/4885HPGD 1044/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | HDAC8 2177/4885HDAC6 1424/4885HPGD 1044/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | HDAC8 1811/4885HDAC6 1435/4885HPGD 483/4885 |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | HDAC8 1811/4885HDAC6 1435/4885HPGD 483/4885 |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | HDAC8 826/4885HDAC6 328/4885HPGD 1365/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | HDAC8 381/4885HDAC6 66/4885HPGD 372/4885 |
| US-20170196908-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | HDAC8 2177/4885HDAC6 1424/4885HPGD 1044/4885 |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TYR, HRH2 | HDAC8 942/4885HDAC6 283/4885HPGD 584/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | HDAC8 826/4885HDAC6 328/4885HPGD 1365/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | HDAC8 826/4885HDAC6 328/4885HPGD 1365/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | HDAC8 826/4885HDAC6 328/4885HPGD 1365/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | HDAC8 2177/4885HDAC6 1424/4885HPGD 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.